A personal reflection on the life, legacy, and controversies of DNA co-discoverer James Watson, following his death at age 97.

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of editing human embryos to make disease-free children.

Artificial intelligence (AI) and machine learning partnered with big data generation at unprecedented scale is transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. From generative AI to unlock novel drug candidates to virtual cells that gleam insights across multimodal biology, we are witnessing the cusp of an exponential curve of AI innovation that is poised to enhance and perhaps overhaul the design and validation of novel therapeutics. In 2024, GEN debuted our virtual summit, The State of AI in Drug Discovery, which drew a record audience. This year’s summit provides a platform for an outstanding group of researchers, evangelists and entrepreneurs to showcase the latest advances, applications and challenges regarding the deployment of AI across therapeutic development. The program features many of the most exciting companies and organizations powering the AI revolution, including NVIDIA, Xaira Therapeutics, Recursion, Chan Zuckerberg Initiative, Arc Institute, Generate: Biomedicines, and more! Please join us on October 29th for a dynamic program featuring: A featured presentation with Bo Wang, PhD (Xaira Therapeutics) on the promise of multimodal AI for health care The democratization of small molecule drug discovery with the developers of Boltz-2, Gabriele Corso, PhD (MIT), Regina Barzilay, PhD (MIT), and Najat Khan, PhD (Recursion) Evolving industry trends across the AI therapeutic landscape with Derek Lowe, PhD (Novartis and author of "In the Pipeline"), Molly Gibson, PhD, (Flagship Pioneering), and Stacie Calad-Thomson, PhD (NVIDIA) Building the virtual cell with Theofanis Karaletsos (Chan Zuckerberg Initiative), Emma Lundberg, PhD (Stanford), Hani Goodarzi, PhD (Arc Institute), and Ron Alfa, MD, PhD (Noetik) What’s next for AI in protein design with Surge Biswas, PhD (Nabla Bio), Tharindi Hapuarachchi, PhD (Generate: Biomedicines), and Oliver Vince, PhD (Basecamp Research) Breakout sessions from our event sponsors, Revvity Signals, Benchling, and Telesis Bio. Registration for The State of AI in Drug Discovery is entirely free. Sponsored by

In a scathing public letter, employees of the National Institutes of Health accused the administration of undermining the agency’s work and endangering people’s health.

Leaders from the world of cell and gene therapy shared their personal stories and policy recommendations in an extraordinary roundtable conducted by the FDA in front of its recently-appointed top offi...

Captioning Link: https://bit.ly/4dQaNaz

Three hundred and seven days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being treated.

How the administration is breaking the government, and what that means for all of us.

A new supercomputer named after a winner of the Nobel Prize in chemistry will help power artificial intelligence technology and scientific discoveries from a perch in the hills above the University of...

Statement Global Observatory for Genome Editing Summit Statement: Call for a Charter on Emerging Technologies and Human Dignity May 23, […]

Oscar winner Natalie Portman is set to star in Photograph 51 for The King's Speech director Tom Hooper.

The Trump administration says the canceled funding is about cost efficiency, but data shows that the opposite is happening.

Professor discusses hype by Colossal Biosciences on their supposed dire wolf de-extinction, which is harmful to science.